A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
for
Duchenne Muscular Dystrophy
Location: Norfolk VA, St Louis MO, Little Rock AR,
Sponsor: Sarepta Therapeutics, Inc.
Sex: Male
Age: 2+
Code: NCT04626674
Phase1, Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy